GSK CEO Emma Walmsley at the Financial Times' Global Pharma and Biotech Summit (courtesy Financial Times)
GSK's supply chain 'reset' after Haleon spinoff to ease tariff impact, CEO says
GSK said its decoupling with Haleon is a key reason why it views itself as “well-positioned” in the face of potential pharma-specific tariffs.
When the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
